|
1
|
Finnerty CC, Jeschke MG, Branski LK,
Barret JP, Dziewulski P and Herndon DN: Hypertrophic scarring: The
greatest unmet challenge after burn injury. Lancet. 388:1427–1436.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang J, Li Y, Bai X, Li Y, Shi J and Hu
D: Recent advances in hypertrophic scar. Histol Histopathol.
33:27–39. 2018.PubMed/NCBI
|
|
3
|
Lebonvallet N, Laverdet B, Misery L,
Desmouliere A and Girard D: New insights into the roles of
myofibroblasts and innervation during skin healing and innovative
therapies to improve scar innervation. Exp Dermatol. 27:950–958.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu Z, Ding J, Shankowsky HA and Tredget
EE: The molecular mechanism of hypertrophic scar. J Cell Commun
Signal. 7:239–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamanaka O, Saika S, Ikeda K, Miyazaki K,
Kitano A and Ohnishi Y: Connective tissue growth factor modulates
extracellular matrix production in human subconjunctival
fibroblasts and their proliferation and migration in vitro. Jpn J
Ophthalmol. 52:8–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kiritsi D and Nystrom A: The role of TGF
beta in wound healing pathologies. Mech Ageing Devt. 172:51–58.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Flanders KC: Smad3 as a mediator of the
fibrotic response. Int J Exp Pathol. 85:47–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Terada Y, Hanada S, Nakao A, Kuwahara M,
Sasaki S and Marumo F: Gene transfer of Smad7 using electroporation
of adenovirus prevents renal fibrosis in post-obstructed kidney.
Kidney Int. 61 (1 Suppl):S94–S98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu C, Jiang J, Boye A, Jiang Y and Yang Y:
Compound Astragalus and Salvia miltiorrhiza extract
suppresses rabbits' hypertrophic scar by modulating the TGF-β/Smad
signal. Dermatology. 229:363–368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mun JH, Kim YM, Kim BS, Kim JH, Kim MB and
Ko HC: Simvastatin inhibits transforming growth factor-β1-induced
expression of type I collagen, CTGF, and α-SMA in keloid
fibroblasts. Wound Repair Regen. 22:125–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen
XL, Guo SZ and Gao WY: Troglitazone suppresses transforming growth
factor-beta1-induced collagen type I expression in keloid
fibroblasts. Br J Dermatol. 160:762–770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lynagh T, Webb TI, Dixon CL, Cromer BA and
Lynch JW: Molecular determinants of ivermectin sensitivity at the
glycine receptor chloride channel. J Biol Chem. 286:43913–43924.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dominguez-Gomez G, Chavez-Blanco A,
Medina-Franco JL, Saldivar-Gonzalez F, Flores-Torrontegui Y, Juarez
M, Diaz-Chavez J, Gonzalez-Fierro A and Duenas-Gonzalez A:
Ivermectin as an inhibitor of cancer stem-like cells. Mol Med Rep.
17:3397–3403. 2018.PubMed/NCBI
|
|
14
|
Deeks ED: Ivermectin: A review in rosacea.
Am J Clin Dermatol. 16:447–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang B, Zhu B, Liang Y, Bi L, Hu Z, Chen
B, Zhang K and Zhu J: Asiaticoside suppresses collagen expression
and TGF-β/Smad signaling through inducing Smad7 and inhibiting
TGF-βRI and TGF-βRII in keloid fibroblasts. Arch Dermatol Res.
303:563–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qin T, Lu XT, Li YG, Liu Y, Yan W, Li N
and Sun YY: Effect of Period 2 on the proliferation, apoptosis and
migration of osteosarcoma cells, and the corresponding mechanisms.
Oncol Lett. 16:2668–2674. 2018.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sidgwick GP and Bayat A: Extracellular
matrix molecules implicated in hypertrophic and keloid scarring. J
Eur Acad Dermatol Venereol. 26:141–152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verrecchia F and Mauviel A: Transforming
growth factor-beta and fibrosis. World J Gastroenterol.
13:3056–3062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kajdaniuk D, Marek B, Borgiel-Marek H and
Kos-Kudla B: Transforming growth factor β1 (TGFβ1) in physiology
and pathology. Endokrynol Pol. 64:384–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu R and Cen Y: Transforming growth factor
beta1/Smad3 signal transduction pathway and post-traumatic scar
formation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 26:330–335.
2012.(In Chinese). PubMed/NCBI
|
|
22
|
Leask A and Abraham DJ: TGF-beta signaling
and the fibrotic response. FASEB J. 18:816–827. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang CJ, Yen YH, Hung LY, Wang SH, Pu CM,
Chien HF, Tsai JS, Lee CW, Yen FL and Chen YL: Thalidomide inhibits
fibronectin production in TGF-β1-treated normal and keloid
fibroblasts via inhibition of the p38/Smad3 pathway. Biochem
Pharmacol. 85:1594–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Biernacka A, Dobaczewski M and
Frangogiannis NG: TGF-beta signaling in fibrosis. Growth Factors.
29:196–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chin GS, Liu W, Peled Z, Lee TY,
Steinbrech DS, Hsu M and Longaker MT: Differential expression of
transforming growth factor-beta receptors I and II and activation
of Smad 3 in keloid fibroblasts. Plast Reconstr Surg. 108:423–429.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Gao Z, Shi Y, Sun Y, Lin Z, Jiang
H, Hou T, Wang Q, Yuan X, Zhu X, et al: Inhibition of Smad3
expression decreases collagen synthesis in keloid disease
fibroblasts. J Plast Reconstr Aesthet Surg. 60:1193–1199. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gauglitz GG, Korting HC, Pavicic T,
Ruzicka T and Jeschke MG: Hypertrophic Scarring and Keloids:
Pathomechanisms and current and emerging treatment strategies. Mol
Med. 17:113–125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Linge C, Richardson J, Vigor C, Clayton E,
Hardas B and Rolfe K: Hypertrophic scar cells fail to undergo a
form of apoptosis specific to contractile collagen-the role of
tissue transglutaminase. J Invest Dermatol. 125:72–82. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo S, Benathan M, Raffoul W, Panizzon RG
and Egloff DV: Abnormal balance between proliferation and apoptotic
cell death in fibroblasts derived from keloid lesions. Plast
Reconstr Surg. 107:87–96. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wolfram D, Tzankov A, Pulzl P and
Piza-Katzer H: Hypertrophic scars and keloids-a review of their
pathophysiology, risk factors, and therapeutic management. Dermatol
Surg. 35:171–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu L, Zhu YJ, Yang X, Guo ZJ, Xu WB and
Tian XL: Effect of TGF-beta/Smad signaling pathway on lung
myofibroblast differentiation. Acta Pharmacol Sin. 28:382–391.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Conte E, Gili E, Fagone E, Fruciano M,
Iemmolo M and Vancheri C: Effect of pirfenidone on proliferation,
TGF-β-induced myofibroblast differentiation and fibrogenic activity
of primary human lung fibroblasts. Eur J Pharm Sci. 58:13–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Darby IA, Laverdet B, Bonté F and
Desmoulière A: Fibroblasts and myofibroblasts in wound healing.
Clin Cosmet Investig Dermatol. 7:301–311. 2014.PubMed/NCBI
|
|
34
|
Meran S and Steadman R: Fibroblasts and
myofibroblasts in renal fibrosis. Int J Exp Patho. 92:158–167.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Colwell AS, Phan TT, Kong W, Longaker MT
and Lorenz PH: Hypertrophic scar fibroblasts have increased
connective tissue growth factor expression after transforming
growth factor-beta stimulation. Plast Reconstr Surg. 116:1387–1992.
2005. View Article : Google Scholar : PubMed/NCBI
|
